Contractor Advisory Committee (CAC) - JE Part B
Contractor Advisory Committee (CAC)
On this page, view the below CAC related information.
- Upcoming Meetings and Related Documents
- Previous Meetings and Related Documents
Noridian A/B MAC may host CAC meetings for subject matter expert consultation regarding published literature in the development of Local Coverage Determinations (LCDs). A CAC panel is recruited and asked a series of key questions from clinical literature related to a specific topic. The discussions between CAC panelists and Contractor Medical Directors are recorded and transcribed so that they are available to the public. Interested stakeholders are invited to listen at the time of the meeting. The A/B MAC shall include a summary of insights and recommendations from the CAC regarding the literature in the final LCD. The CAC purpose is to:
- Serve in an advisory capacity as representatives of their constituency to review the quality of the evidence used in the development of an LCD; and
- Be used as a formal mechanism for healthcare professionals to be informed of the evidence used in developing the LCD; and
- Promote communications between Noridian and the healthcare community.
The CAC is composed of subject matter experts, healthcare professionals and other members as appropriate to the topic being considered. The CAC is used to supplement the MAC’s internal expertise and to ensure an unbiased and contemporary consideration of "state of the art" technology and science. CAC members are valued for their background, education, experience and/or expertise in a wide variety of scientific, clinical, and other related fields.
Participation in the CAC is voluntary. Noridian does not provide an honorarium or other forms of compensation to members. All CAC meetings will be open to the public to attend and observe.
Meetings occur as needed for the development of LCDs. Non-CAC members may participate in listen-only mode via teleconference.
|All||08/16/23||Cervical Fusion||1 p.m. - 4 p.m. CT||
|All||10/19/23||Botulinum Toxins||1 p.m. - 4 p.m. CT
(2 p.m. - 5 p.m. ET)
|05/25/23||Non-Invasive Technology for Coronary Artery Plaque Analysis|
|04/27/23||Trigger Point Injections|
|02/28/23||Remote Physiologic Monitoring (RPM) and Remote Therapeutic Monitoring (RTM) for Non-implantable Devices|
|01/05/23||Micro-Invasive Glaucoma Surgery (MIGS)|
|11/17/22||Molecular Diagnostic Testing for Acute Rejection in Heart or Lung Allografts|
|11/16/22||Molecular Diagnostic Testing for Acute Rejection in Kidney or Liver Allografts|
|03/10/22||Multi-Jurisdictional Contractor Advisory Committee (CAC) for Sacroiliac Joint Injections and Procedures|
|12/07/21||MolDX: Predictive Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis CAC Meeting|
|10/12/21||MolDX: Molecular Testing for Risk Stratification of Upper Gastrointestinal Cancer|
|05/12/21||Amniotic Product Injections for Musculoskeletal Indications, Non-Wound|
|02/11/21||Epidural Interventions for Chronic Pain Management|
|01/11/21||Molecular Diagnostic Panel Testing for Pathogens|
|05/28/20||Facet Joint and Medial Nerve Branch Procedures|
|04/28/20||Wound Care and Skin Substitutes|
|11/12/19||Fluid Jet System in the Treatment of Benign Prostatic Hyperplasia|
|06/18/19||Fractional Flow Reserve computed tomography (FFRct)|
Email "LCD Reconsideration" at firstname.lastname@example.org with questions regarding CAC meeting, process, or membership.
Last Updated Wed, 06 Sep 2023 18:44:44 +0000